Skip to main content
. Author manuscript; available in PMC: 2014 Apr 3.
Published in final edited form as: Sci Transl Med. 2013 Apr 3;5(179):179ra43. doi: 10.1126/scitranslmed.3005265

Figure 2. Altered cytokine milieu and activation of intracellular Stat5 in chronic GVHD.

Figure 2

(A–B)Lymphocyte counts and CD4 T cell counts in peripheral blood from healthy donors and chronic GVHD patients (Cohort 1). Box plots in each figure depict the 75th percentile, median and 25th percentile values and whiskers represent maximum and minimum values. (C) Plasma concentrations of IL-2, IL-7 and IL-15 from healthy donors and HSCT patients. (D) Ratio ofplasma cytokine concentration to CD4 T cell number for each patient group. (E) Expression of phosphorylated Stat5 (pStat5) in CD4 gated Tcon (blue) and Treg (red) from healthy donors and patients with and without chronic GVHD. Representative panels are shown. (F) Expression of pStat5 in Tcon and Treg subsets from 25 healthy donors and 45 HSCT patients. The expression of pStat5 in Tcon was significantly greater than Treg in patients with severe cGVHD (p < 0.005, Wilcoxon-signed-rank test), while pStat5 expression in other groups did not show significant differences between Treg and Tcon. (G) Ratio of Treg-pStat5 MFI to Tcon-pStat5 MFI in healthy donors and transplant patients. Treg-pStat5/Tcon-pStat5 ratio in severe chronic GVHD was significantly lower than in patients without GVHD (p < 0.001, Wilcoxon-rank-sum test).